1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of Australians every year, thanks to a major expansion of the PBS.
The drug Kisqali (ribociclib), which was previously available for advanced cases, is now being subsidised for a broader group of patients, specifically those with early-stage, hormone receptor-positive, HER2 negative, lymph node-positive breast cancer who are at high risk of their cancer returning after surgery.